

Davide Franceschini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7727766/publications.pdf>

Version: 2024-02-01

119
papers

2,091
citations

201674

27
h-index

330143

37
g-index

121
all docs

121
docs citations

121
times ranked

3206
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiomics-based prognosis classification for high-risk prostate cancer treated with radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 710-718.	2.0	5
2	Oligoscore: a clinical score to predict overall survival in patients with oligometastatic disease treated with stereotactic body radiotherapy. <i>Acta Oncologica</i> , 2022, 61, 553-559.	1.8	2
3	Unmet needs in the management of unresectable stage III non-small cell lung cancer: a review after the "radio talk"™ webinars. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 549-559.	2.4	1
4	Locally Advanced Non-Small Cell Lung Cancer: Clinical Outcome, Toxicity and Predictive Factors in Patients Treated with Hypofractionated Sequential or Exclusive Radiotherapy. <i>Current Oncology</i> , 2022, 29, 4893-4901.	2.2	0
5	Preliminary Results of a Randomized Study on Postmenopausal Women With Early Stage Breast Cancer: Adjuvant Hypofractionated Whole Breast Irradiation Versus Accelerated Partial Breast Irradiation (HYPAB Trial). <i>Clinical Breast Cancer</i> , 2021, 21, 231-238.	2.4	15
6	Moderate hypofractionated radiotherapy for post-operative treatment of prostate cancer: long-term outcome and pattern of toxicity. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 133-140.	2.0	6
7	Dose coverage impacts local control in ultra-central lung oligometastases treated with stereotactic radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 396-404.	2.0	8
8	Bilateral radiation recall pneumonitis during immunotherapy for an advanced renal cell carcinoma: A challenging case enhances the need for a multidisciplinary approach. <i>European Journal of Cancer</i> , 2021, 143, 75-77.	2.8	7
9	Stereotactic body radiotherapy in hepatocellular carcinoma: patient selection and predictors of outcome and toxicity. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 927-936.	2.5	9
10	Comparing hypofractionated and conventionally fractionated whole breast irradiation for patients with ductal carcinoma in situ after breast conservation: a propensity score-matched analysis from a national multicenter cohort (COBCG-02 study). <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2069-2077.	2.5	3
11	Dosimetric impact of volumetric modulated arc therapy for nasopharyngeal cancer treatment. <i>Reports of Practical Oncology and Radiotherapy</i> , 2021, 26, 101-110.	0.6	3
12	Salvage radiotherapy for oligo-progressive malignant pleural mesothelioma. <i>Lung Cancer</i> , 2021, 152, 1-6.	2.0	7
13	OLIGO-AIRO: a national survey on the role of radiation oncologist in the management of OLIGO-metastatic patients on the behalf of AIRO. <i>Medical Oncology</i> , 2021, 38, 48.	2.5	4
14	Critical Re-Evaluation of a Failure Mode Effect Analysis in a Radiation Therapy Department After 10 Years. <i>Practical Radiation Oncology</i> , 2021, 11, e329-e338.	2.1	4
15	A reply to "managing oligoprogressive malignant pleural mesothelioma with stereotactic body radiation therapy". <i>Lung Cancer</i> , 2021, 157, 165-166.	2.0	2
16	Radiomics in the Setting of Neoadjuvant Radiotherapy: A New Approach for Tailored Treatment. <i>Cancers</i> , 2021, 13, 3590.	3.7	21
17	Ipsilateral Breast Cancer Recurrence: Characteristics, Treatment, and Long-Term Oncologic Results at a High-Volume Center. <i>Clinical Breast Cancer</i> , 2021, 21, 329-336.	2.4	7
18	Knowing When to Use Stereotactic Ablative Radiation Therapy in Oligometastatic Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 7009-7031.	1.9	0

#	ARTICLE	IF	CITATIONS
19	Phase II trial of stereotactic body radiation therapy on adrenal gland metastases: evaluation of efficacy and impact on hormonal production. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3619-3625.	2.5	5
20	The NIPRO Study: An Observational, Retrospective, Multicenter Study on the Safety of the Radiotherapy and Immunotherapy Combination for Advanced-Stage NSCLC. <i>Clinical Lung Cancer</i> , 2021, 22, e767-e773.	2.6	8
21	Impact of hypofractionated schemes in radiotherapy for locally advanced head and neck cancer patients. <i>Laryngoscope</i> , 2020, 130, E163-E170.	2.0	11
22	Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 213-221.	2.0	29
23	Volumetric Modulated Arc Therapy After Lung Sparing Surgery for Malignant Pleural Mesothelioma: A Single Institution Experience. <i>Clinical Lung Cancer</i> , 2020, 21, 86-93.	2.6	4
24	Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetings. <i>Radiologia Medica</i> , 2020, 125, 214-219.	7.7	10
25	The Potential Role of Intensity-modulated Proton Therapy in the Regional Nodal Irradiation of Breast Cancer: A Treatment Planning Study. <i>Clinical Oncology</i> , 2020, 32, 26-34.	1.4	22
26	A radiomic approach to predicting nodal relapse and disease-specific survival in patients treated with stereotactic body radiation therapy for early-stage non-small cell lung cancer. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 922-931.	2.0	12
27	Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question. <i>British Journal of Radiology</i> , 2020, 93, 20190627.	2.2	11
28	Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with a curative intent. <i>Lung Cancer</i> , 2020, 141, 1-8.	2.0	17
29	Lung cancer management: monitoring and treating resistance development in third-generation EGFR TKIs. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 743-753.	2.4	1
30	Oligometastasis and local ablation in the era of systemic targeted and immunotherapy. <i>Radiation Oncology</i> , 2020, 15, 92.	2.7	31
31	Liver Metastases-directed Therapy in the Management of Oligometastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 480-486.	2.4	10
32	Hypofractionated Whole Breast Irradiation and Simultaneous Integrated Boost in Large-breasted Patients: Long-term Toxicity and Cosmesis. <i>Clinical Breast Cancer</i> , 2020, 20, 527-533.	2.4	11
33	Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2289-2297.	2.5	12
34	Volumetric modulated arc therapy versus intensity-modulated proton therapy in the postoperative irradiation of thymoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2267-2276.	2.5	7
35	Phase II trial of high dose stereotactic body radiation therapy for lymph node oligometastases. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 565-573.	3.3	9
36	Assessing the role of Stereotactic Body Radiation Therapy in a large cohort of patients with lymph node oligometastases: Does it affect systemic treatment's intensification?. <i>Radiotherapy and Oncology</i> , 2020, 150, 184-190.	0.6	12

#	ARTICLE	IF	CITATIONS
37	The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: State of the art. Critical Reviews in Oncology/Hematology, 2020, 148, 102894.	4.4	27
38	Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1227-1234.	2.5	5
39	Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkinâ€™s lymphoma. Assessment of risk of toxicity and secondary cancer induction. Radiation Oncology, 2020, 15, 12.	2.7	14
40	Current radiotherapy techniques in NSCLC: challenges and potential solutions. Expert Review of Anticancer Therapy, 2020, 20, 387-402.	2.4	24
41	Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer. Strahlentherapie Und Onkologie, 2020, 196, 608-616.	2.0	8
42	Stereotactic Radiotherapy for Ultra-Central Lung Oligometastases in Non-Small-Cell Lung Cancer. Cancers, 2020, 12, 885.	3.7	10
43	Adjuvant volumetric modulated arc therapy compared to 3D conformal radiation therapy for newly diagnosed soft tissue sarcoma of the extremities: outcome and toxicity evaluation. British Journal of Radiology, 2019, 92, 20190252.	2.2	8
44	RapidPlan knowledge based planning: iterative learning process and model ability to steer planning strategies. Radiation Oncology, 2019, 14, 187.	2.7	39
45	Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach. PLoS ONE, 2019, 14, e0224027.	2.5	5
46	Predictive factors for survival outcomes of oligometastatic prostate cancer patients treated with metastases-directed therapy: a recursive partitioning-based analysis. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2469-2479.	2.5	14
47	Surgery Followed by Hypofractionated Radiosurgery on the Tumor Bed in Oligometastatic Patients With Large Brain Metastases. Results of a Phase 2 Study. International Journal of Radiation Oncology Biology Physics, 2019, 105, 1095-1105.	0.8	15
48	Can thoracic nodes oligometastases be safely treated with image guided hypofractionated radiation therapy?. British Journal of Radiology, 2019, 92, 20181026.	2.2	4
49	Computed tomography based radiomic signature as predictive of survival and local control after stereotactic body radiation therapy in pancreatic carcinoma. PLoS ONE, 2019, 14, e0210758.	2.5	58
50	Predicting survival and local control after radiochemotherapy in locally advanced head and neck cancer by means of computed tomography based radiomics. Strahlentherapie Und Onkologie, 2019, 195, 805-818.	2.0	36
51	Postmastectomy radiation therapy using VMAT technique for breast cancer patients with expander reconstruction. Medical Oncology, 2019, 36, 48.	2.5	25
52	Linac-based stereotactic body radiation therapy vs moderate hypofractionated radiotherapy in prostate cancer: propensity-score based comparison of outcome and toxicity. British Journal of Radiology, 2019, 92, 20190021.	2.2	6
53	Reirradiation of Locally Recurrent Prostate Cancer With Volumetric Modulated Arc Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 104, 614-621.	0.8	22
54	Extra-pleural pneumonectomy in the era of image-guided intensity-modulated radiotherapy. Radiologia Medica, 2019, 124, 854-859.	7.7	9

#	ARTICLE	IF	CITATIONS
55	Predictive Factors for Response and Survival in a Cohort of Oligometastatic Patients Treated With Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 104, 111-121.	0.8	30
56	Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group. Radiologia Medica, 2019, 124, 662-670.	7.7	33
57	Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer. Future Oncology, 2019, 15, 3775-3782.	2.4	10
58	Radiotherapy for oligometastatic cancer: a survey among radiation oncologists of Lombardy (AIRO-Lombardy), Italy. Radiologia Medica, 2019, 124, 315-322.	7.7	11
59	Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy. Radiotherapy and Oncology, 2019, 133, 220-226.	0.6	49
60	Hypofractionated radiation therapy in the management of locally advanced NSCLC: a narrative review of the literature on behalf of the Italian Association of Radiation Oncology (AIRO) "Lung Working Group. Radiologia Medica, 2019, 124, 136-144.	7.7	8
61	Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma. Journal of Urology, 2019, 201, 70-76.	0.4	44
62	Title is missing!. , 2019, 14, e0224027.		0
63	Title is missing!. , 2019, 14, e0224027.		0
64	Title is missing!. , 2019, 14, e0224027.		0
65	Title is missing!. , 2019, 14, e0224027.		0
66	Title is missing!. , 2019, 14, e0224027.		0
67	Title is missing!. , 2019, 14, e0224027.		0
68	Applying Lean-Six-Sigma Methodology in radiotherapy: Lessons learned by the breast daily repositioning case. Radiotherapy and Oncology, 2018, 127, 326-331.	0.6	17
69	Hypofractionated volumetric modulated arc therapy in ductal carcinoma <i>in situ</i> : toxicity and cosmetic outcome from a prospective series. British Journal of Radiology, 2018, 91, 20170634.	2.2	4
70	Critical Appraisal of the Risk of Secondary Cancer Induction From Breast Radiation Therapy With Volumetric Modulated Arc Therapy Relative to 3D Conformal Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 100, 785-793.	0.8	29
71	Radiation therapy in small cell lung cancer: a national Italian survey. Radiologia Medica, 2018, 123, 554-560.	7.7	3
72	Long-Term Follow-Up of Patients with Metastatic Epidural Spinal Cord Compression from Breast Cancer Treated with Surgery Followed by Radiotherapy. World Neurosurgery, 2018, 110, e281-e286.	1.3	5

#	ARTICLE	IF	CITATIONS
73	Stereotactic Body Radiation Therapy in Oligometastatic Ovarian Cancer: A Promising Therapeutic Approach. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1507-1513.	2.5	35
74	Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). <i>Cancer Treatment Reviews</i> , 2018, 71, 76-87.	7.7	38
75	Critical Appraisal of the Treatment Planning Performance of Volumetric Modulated Arc Therapy by Means of a Dual Layer Stacked Multileaf Collimator for Head and Neck, Breast, and Prostate. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381880388.	1.9	26
76	Role of 11C-choline PET/CT in radiation therapy planning of patients with prostate cancer. <i>Nuclear Medicine Communications</i> , 2018, 39, 951-956.	1.1	8
77	The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer. <i>Cancer Medicine</i> , 2018, 7, 4379-4386.	2.8	29
78	Hypofractionation with simultaneous boost in breast cancer patients receiving adjuvant chemotherapy: A prospective evaluation of a case series and review of the literature. <i>Breast</i> , 2018, 42, 31-37.	2.2	14
79	Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 295-301.	1.9	80
80	The role of SBRT in oligometastatic patients with liver metastases from breast cancer. <i>Reports of Practical Oncology and Radiotherapy</i> , 2017, 22, 163-169.	0.6	14
81	Radical hypo-fractionated radiotherapy with volumetric modulated arc therapy in lung cancer. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 385-391.	2.0	7
82	Outcome appraisal of patients with limited brain metastases (BMs) from non small cell lung cancer (NSCLC) treated with different local therapeutic strategies: a single institute evaluation. <i>British Journal of Radiology</i> , 2017, 90, 20170022.	2.2	5
83	Organs at risk in lung SBRT. <i>Physica Medica</i> , 2017, 44, 131-138.	0.7	24
84	RapidPlan head and neck model: the objectives and possible clinical benefit. <i>Radiation Oncology</i> , 2017, 12, 73.	2.7	66
85	Role of stereotactic body radiation therapy for lung metastases from radio-resistant primary tumours. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1293-1299.	2.5	26
86	Stereotactic/hypofractionated body radiation therapy as an effective treatment for lymph node metastases from colorectal cancer: an institutional retrospective analysis. <i>British Journal of Radiology</i> , 2017, 90, 20170422.	2.2	13
87	Role of extra cranial stereotactic body radiation therapy in the management of Stage IV melanoma. <i>British Journal of Radiology</i> , 2017, 90, 20170257.	2.2	14
88	Dosimetric trade-offs in breast treatment with VMAT technique. <i>British Journal of Radiology</i> , 2017, 90, 20160701.	2.2	51
89	Outcome Evaluation of Patients with Limited Brain Metastasis From Malignant Melanoma, Treated with Surgery, Radiation Therapy, and Targeted Therapy. <i>World Neurosurgery</i> , 2017, 105, 184-190.	1.3	13
90	Minimally Invasive Stereotactical Radio-ablation of Adrenal Metastases as an Alternative to Surgery. <i>Cancer Research and Treatment</i> , 2017, 49, 20-28.	3.0	34

#	ARTICLE	IF	CITATIONS
91	Radiomics based analysis to predict local control and survival in hepatocellular carcinoma patients treated with volumetric modulated arc therapy. BMC Cancer, 2017, 17, 829.	2.6	77
92	Critical appraisal of the role of volumetric modulated arc therapy in the radiation therapy management of breast cancer. Radiation Oncology, 2017, 12, 200.	2.7	26
93	Outcome Evaluation of HER2 Breast Cancer Patients with Limited Brain Metastasis. Anticancer Research, 2017, 37, 7057-7062.	1.1	6
94	High-quality Linac-based Stereotactic Body Radiation Therapy with Flattening Filter Free Beams and Volumetric Modulated Arc Therapy for Low-Intermediate Risk Prostate Cancer. A Mono-institutional Experience with 90 Patients. Clinical Oncology, 2016, 28, e173-e178.	1.4	33
95	Hypo-fractionated stereotactic radiotherapy alone using volumetric modulated arc therapy for patients with single, large brain metastases unsuitable for surgical resection. Radiation Oncology, 2016, 11, 76.	2.7	59
96	Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases?. Cancer Treatment Reviews, 2016, 50, 1-8.	7.7	30
97	Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results. Radiation Oncology, 2016, 11, 120.	2.7	38
98	Role of Stereotactic Body Radiation Therapy with Volumetric-Modulated Arcs and High-Intensity Photon Beams for the Treatment of Abdomino-Pelvic Lymph-Node Metastases. Cancer Investigation, 2016, 34, 348-354.	1.3	16
99	Stereotactic body radiation therapy: A promising chance for oligometastatic breast cancer. Breast, 2016, 26, 11-17.	2.2	51
100	Prognostic factors in patients with locally advanced head and neck cancer treated with concurrent radiochemotherapy. Radiologia Medica, 2016, 121, 229-237.	7.7	7
101	CyberKnife stereotactic radiotherapy for isolated recurrence in the prostatic bed. World Journal of Urology, 2016, 34, 311-317.	2.2	28
102	Volumetric modulated arc therapy for thoracic node metastases: a safe and effective treatment for a neglected disease. Oncotarget, 2016, 7, 53321-53329.	1.8	13
103	Toxicity profile and early clinical outcome for advanced head and neck cancer patients treated with simultaneous integrated boost and volumetric modulated arc therapy. Radiation Oncology, 2015, 10, 224.	2.7	22
104	Cyberknife Treatment for Low and Intermediate Risk Prostate Cancer. Cancer Investigation, 2015, 33, 188-192.	1.3	7
105	Evaluation of the Risk of Grade 3 Oral and Pharyngeal Dysphagia Using Atlas-Based Method and Multivariate Analyses of Individual Patient Dose Distributions. International Journal of Radiation Oncology Biology Physics, 2015, 93, 507-515.	0.8	36
106	Stereotactic radiotherapy for isolated nodal recurrence of prostate cancer. World Journal of Urology, 2015, 33, 1197-1203.	2.2	35
107	Docetaxel in Castration-Resistant Prostate Cancer: A Single-Centre Experience. Cancer Investigation, 2014, 32, 445-450.	1.3	0
108	Neoadjuvant oxaliplatin and 5-fluorouracil with concurrent radiotherapy in patients with locally advanced rectal cancer: a single institution experience. Radiologia Medica, 2013, 118, 570-582.	7.7	3

#	ARTICLE	IF	CITATIONS
109	Treatment of invasive male breast cancer: a 40-year single-institution experience. <i>Radiologia Medica</i> , 2013, 118, 476-486.	7.7	2
110	Predictive factors of [18F]-Choline PET/CT in 170 patients with increasing PSA after primary radical treatment. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 521-528.	2.5	32
111	Radiotherapy boost dose-escalation for invasive breast cancer after breast-conserving surgery: 2093 Patients treated with a prospective margin-directed policy. <i>Radiotherapy and Oncology</i> , 2013, 108, 273-278.	0.6	20
112	Role of radiotherapy boost in women with ductal carcinoma in situ: A single-center experience in a series of 389 patients. <i>European Journal of Surgical Oncology</i> , 2013, 39, 613-618.	1.0	29
113	Prognostic Role of Human Epidermal Growth Factor Receptor 2 Status in Premenopausal Early Breast Cancer Treated With Adjuvant Tamoxifen. <i>Clinical Breast Cancer</i> , 2013, 13, 247-253.	2.4	10
114	Simultaneous integrated boostâ€“intensityâ€“modulated radiotherapy in head and neck cancer. <i>Laryngoscope</i> , 2013, 123, E97-103.	2.0	16
115	Application of helical tomotherapy for the treatment of a right atrium angiosarcoma: a case report. <i>Tumori</i> , 2013, 99, e233-6.	1.1	2
116	Pediatric Primary Anaplastic Ganglioglioma: A Case Report and Review of the Literature. <i>Pediatric Neurosurgery</i> , 2012, 48, 35-41.	0.7	13
117	Prognostic factors and clinical features in patients with leptomeningeal metastases from breast cancer: a single center experience. <i>Journal of Chemotherapy</i> , 2012, 24, 279-284.	1.5	27
118	Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph nodeâ€“negative breast cancer. <i>Cancer</i> , 2012, 118, 3236-3243.	4.1	39
119	Adjuvant Radiotherapy for a Prostate Cancer After Renal Transplantation and Review of the Literature. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 1282-1286.	1.3	13